Agios Shares Fall After FDA Extends Mitapivat Review for Sickle Cell Disease
FDA pushed back the mitapivat SCD decision to Feb 2027 after a major amendment. Agios stock dropped on the delay.
FDA pushed back the mitapivat SCD decision to Feb 2027 after a major amendment. Agios stock dropped on the delay.
The company will cease development of the drug and conserve cash after missing clinical endpoints.
Iovance stock plunged on flat 24.6% response rates in its lung cancer trial, despite stronger results in a biomarker subgroup.
Hims & Hers shares rose after HHS said it will temporarily allow compounding pharmacies to produce six popular peptides, including BPC-157, while regulators review formal approval.
Phase 3 trial shows petosemtamab plus Keytruda halves risk of death versus Keytruda alone in first-line PD-L1+ recurrent/metastatic HNSCC.
FDA accepts Palvella’s QTORIN rapamycin NDA with Priority Review for microcystic lymphatic malformations. Target decision date is February 28, 2027.